Institute of Rheumatology, Prague, Czech Republic.
Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Sci Rep. 2021 Jan 7;11(1):1. doi: 10.1038/s41598-020-79139-8.
Our previous study demonstrated increased expression of Heat shock protein (Hsp) 90 in the skin of patients with systemic sclerosis (SSc). We aimed to evaluate plasma Hsp90 in SSc and characterize its association with SSc-related features. Ninety-two SSc patients and 92 age-/sex-matched healthy controls were recruited for the cross-sectional analysis. The longitudinal analysis comprised 30 patients with SSc associated interstitial lung disease (ILD) routinely treated with cyclophosphamide. Hsp90 was increased in SSc compared to healthy controls. Hsp90 correlated positively with C-reactive protein and negatively with pulmonary function tests: forced vital capacity and diffusing capacity for carbon monoxide (DLCO). In patients with diffuse cutaneous (dc) SSc, Hsp90 positively correlated with the modified Rodnan skin score. In SSc-ILD patients treated with cyclophosphamide, no differences in Hsp90 were found between baseline and after 1, 6, or 12 months of therapy. However, baseline Hsp90 predicts the 12-month change in DLCO. This study shows that Hsp90 plasma levels are increased in SSc patients compared to age-/sex-matched healthy controls. Elevated Hsp90 in SSc is associated with increased inflammatory activity, worse lung functions, and in dcSSc, with the extent of skin involvement. Baseline plasma Hsp90 predicts the 12-month change in DLCO in SSc-ILD patients treated with cyclophosphamide.
我们之前的研究表明，全身性硬皮病（SSc）患者的皮肤中热休克蛋白（Hsp）90 的表达增加。我们旨在评估 SSc 患者的血浆 Hsp90 并描述其与 SSc 相关特征的关系。招募了 92 名 SSc 患者和 92 名年龄/性别匹配的健康对照者进行横断面分析。纵向分析包括 30 名常规接受环磷酰胺治疗的 SSc 相关间质性肺病（ILD）患者。与健康对照组相比，SSc 患者的 Hsp90 增加。Hsp90 与 C 反应蛋白呈正相关，与肺功能测试：用力肺活量和一氧化碳弥散量（DLCO）呈负相关。在弥漫性皮肤 SSc（dcSSc）患者中，Hsp90 与改良罗达诺皮肤评分呈正相关。在接受环磷酰胺治疗的 SSc-ILD 患者中，基线与治疗后 1、6 和 12 个月之间的 Hsp90 无差异。然而，基线 Hsp90 可预测 12 个月时 DLCO 的变化。本研究表明，与年龄/性别匹配的健康对照组相比，SSc 患者的血浆 Hsp90 水平升高。SSc 中升高的 Hsp90 与炎症活性增加、肺功能下降有关，在 dcSSc 中与皮肤受累程度有关。基线血浆 Hsp90 可预测接受环磷酰胺治疗的 SSc-ILD 患者的 12 个月时 DLCO 的变化。
